Short- and Long-Term Outcomes of Mirikizumab for Ulcerative Colitis: A Real-World Multicenter Retrospective Cohort Study from the INSIGHT study
MIR demonstrated durable effectiveness and a favorable safety profile over 52 weeks in a real-world UC population, including those with prior treatment failures. These findings support MIR as a viable long-term therapeutic option in routine clinical practice.
Authors
- Takeshi Kuno
- Tsunaki Sawada (ORCID: https://orcid.org/0000-0002-4779-9708)
- Shun Hattori
- Kentaro Murate
- Issei Hasegawa (ORCID: https://orcid.org/0000-0001-7726-4061)
- Noboru Urata
- Genta Uchida (ORCID: https://orcid.org/0000-0003-2634-7865)
- Rinzaburo Matsuura
- Takahiro Nishikawa (ORCID: https://orcid.org/0000-0003-4600-6902)
- Ayako Ohashi
- Masanao Nakamura
- Takeshi Yamamura
- Toshihisa Fujiyoshi
- Hiroto Suzuki
- Nobuyuki Miyake
- Keiko Maeda
- Eri Ishikawa
- Hiroki Kawashima
Publication Details
- Journal
- Digestion
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1159/000551500
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00